Invion Stock

Invion Capital Expenditures

Capital Expenditures (CapEx) of Invion (IVX.AX) as of Sep 4, 2026.

Capital Expenditures

0.00AUD

Last updated:

Capital Expenditures (CapEx) of Invion is 2026 0.00 AUD. Capital Expenditures (CapEx) of Invion was 2025 -900,000.00 AUD. It decreases by % higher compared to the previous year.

The Invion Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2015
-245,800.00 AUD
Jan 1, 2016
0.00 AUD
Jan 1, 2019
-6,100.00 AUD
Jan 1, 2020
0.00 AUD
Jan 1, 2022
-7.25 M AUD
Jan 1, 2023
-2.58 M AUD
Jan 1, 2024
-900,000.00 AUD
Jan 1, 2025
0.00 AUD
The Invion Capital Expenditures history
YEARCapital ExpendituresYoY
0.00AUD-100.00%
-900,000.00AUD-65.06%
-2.58 MAUD-64.47%
-7.25 MAUD—
0.00AUD-100.00%
-6,100.00AUD—
0.00AUD-100.00%
-245,800.00AUD-12.21%
-280,000.00AUD—
Access this data via the Eulerpool API
Get Free API Key

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Invion since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Invion historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Cash Flow — Invion

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Invion